About Psylo
Psylo is a company based in Sydney (Australia) founded in 2021 by Josh Ismin and Sam Banister. Psylo has raised $14.18 million across 3 funding rounds from investors including Focalpoint Partners, Main Sequence and Lionheart Ventures. Psylo offers products and services including Neuroplastogen Therapies and Pipeline Therapies. Psylo operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
- Headquarter Sydney, Australia
- Founders Josh Ismin, Sam Banister
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Psylo Pty Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.18 M (USD)
in 3 rounds
-
Latest Funding Round
$8 M (USD), Seed
Jun 03, 2024
-
Investors
Focalpoint Partners
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Psylo
Psylo offers a comprehensive portfolio of products and services, including Neuroplastogen Therapies and Pipeline Therapies.
Treatments enhancing neuroplasticity for brain disorders.
Advanced tools for developing neurological treatments.
People of Psylo
Unlock access to complete
Leadership Team
3 people
Lead Team
1 people
Head Team
1 people
Computational Team
1 people
Medicinal Team
1 people
Unlock access to complete
Funding Insights of Psylo
Psylo has successfully raised a total of $14.18M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $8 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Psylo
Psylo has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Focalpoint Partners, Main Sequence and Lionheart Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in deep tech founders.
|
Locked | Locked | Locked | |
|
A venture capital firm focused on transformative technologies is operated.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in health and technology sectors.
|
Locked | Locked | Locked |
Investor details for Psylo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Psylo
Investment portfolio details for Psylo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Psylo
Detailed financials for Psylo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Psylo Comparisons
Peer comparison for Psylo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Psylo
Psylo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of neurological and psychiatric disorders
|
|
| Locked | Locked | Locked |
Psychedelic therapeutics for psychiatric disorders are developed and provided.
|
Detailed competitors of Psylo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Psylo
Complete news archive for Psylo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Psylo
Psylo was founded in 2021.
Psylo is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Josh Ismin is the current CEO of Psylo. They have also founded this company.
Psylo is a funded company, having raised a total of $14.18M across 3 funding rounds to date.
Psylo was founded in 2021 in Sydney, Australia, as a developer of psychedelic-derived therapeutics targeting mental health conditions. Improved treatments against selective serotonin reuptake inhibitors are provided through these drugs, addressing issues such as treatment-resistant depression, anxiety, and addiction. Operations focus on research and development within the biotechnology sector, with activities centered in Australia.
Psylo's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.
Psylo offers Neuroplastogen Therapies and Pipeline Therapies.
Psylo has 13 investors. Key investors include Focalpoint Partners, Main Sequence, Lionheart Ventures, Negev Capital, and XEIA Venture Partners.